S&P 500   2,995.99 (-0.36%)
DOW   26,788.10 (-0.15%)
QQQ   191.85 (-0.80%)
AAPL   239.96 (-0.23%)
FB   182.34 (-3.91%)
MSFT   136.37 (-1.49%)
GOOGL   1,241.20 (-0.25%)
AMZN   1,765.73 (-1.12%)
CGC   21.15 (+3.93%)
NVDA   195.61 (-0.20%)
MU   44.66 (-1.24%)
BABA   169.89 (-2.09%)
GE   9.06 (+3.07%)
TSLA   255.58 (+0.82%)
AMD   31.51 (-1.62%)
T   38.17 (-0.16%)
F   9.07 (+0.44%)
ACB   3.58 (-2.98%)
PRI   125.80 (+0.09%)
NFLX   266.69 (-4.09%)
BAC   31.20 (+0.58%)
GILD   65.86 (+1.00%)
DIS   132.40 (+1.64%)
S&P 500   2,995.99 (-0.36%)
DOW   26,788.10 (-0.15%)
QQQ   191.85 (-0.80%)
AAPL   239.96 (-0.23%)
FB   182.34 (-3.91%)
MSFT   136.37 (-1.49%)
GOOGL   1,241.20 (-0.25%)
AMZN   1,765.73 (-1.12%)
CGC   21.15 (+3.93%)
NVDA   195.61 (-0.20%)
MU   44.66 (-1.24%)
BABA   169.89 (-2.09%)
GE   9.06 (+3.07%)
TSLA   255.58 (+0.82%)
AMD   31.51 (-1.62%)
T   38.17 (-0.16%)
F   9.07 (+0.44%)
ACB   3.58 (-2.98%)
PRI   125.80 (+0.09%)
NFLX   266.69 (-4.09%)
BAC   31.20 (+0.58%)
GILD   65.86 (+1.00%)
DIS   132.40 (+1.64%)
Log in

AcelRx Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ACRX)

$2.19
0.00 (0.00 %)
(As of 10/22/2019 04:00 PM ET)
Today's Range
$2.16
Now: $2.19
$2.21
50-Day Range
$2.05
MA: $2.31
$2.71
52-Week Range
$1.99
Now: $2.19
$5.05
Volume351,648 shs
Average Volume1.52 million shs
Market Capitalization$173.96 million
P/E RatioN/A
Dividend YieldN/A
Beta2.11
AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACRX
CUSIPN/A
Phone650-216-3500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.15 million
Book Value$0.05 per share

Profitability

Net Income$-47,150,000.00
Net Margins-2,327.05%

Miscellaneous

Employees61
Market Cap$173.96 million
Next Earnings Date11/1/2019 (Estimated)
OptionableOptionable

Receive ACRX News and Ratings via Email

Sign-up to receive the latest news and ratings for ACRX and its competitors with MarketBeat's FREE daily newsletter.


AcelRx Pharmaceuticals (NASDAQ:ACRX) Frequently Asked Questions

What is AcelRx Pharmaceuticals' stock symbol?

AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX."

How were AcelRx Pharmaceuticals' earnings last quarter?

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) posted its earnings results on Monday, August, 5th. The specialty pharmaceutical company reported ($0.16) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.23) by $0.07. The specialty pharmaceutical company earned $0.94 million during the quarter, compared to analyst estimates of $1.55 million. View AcelRx Pharmaceuticals' Earnings History.

When is AcelRx Pharmaceuticals' next earnings date?

AcelRx Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, November 1st 2019. View Earnings Estimates for AcelRx Pharmaceuticals.

What price target have analysts set for ACRX?

7 equities research analysts have issued 1 year price objectives for AcelRx Pharmaceuticals' stock. Their predictions range from $6.50 to $10.00. On average, they anticipate AcelRx Pharmaceuticals' stock price to reach $8.08 in the next twelve months. This suggests a possible upside of 269.1% from the stock's current price. View Analyst Price Targets for AcelRx Pharmaceuticals.

What is the consensus analysts' recommendation for AcelRx Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AcelRx Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AcelRx Pharmaceuticals.

What are Wall Street analysts saying about AcelRx Pharmaceuticals stock?

Here are some recent quotes from research analysts about AcelRx Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and ARX-03 or the Sufentanil/Triazolam NanoTab which are in their development stage. Its product ARX-01 is focused on acute post-operative pain, ARX-02 is focused on the treatment of cancer breakthrough pain and ARX-03 is focused on providing mild sedation, anxiety reduction, and pain relief to patients undergoing painful procedures in a physician's office. AcelRx Pharmaceuticals, Inc. is headquartered in Redwood City, California. " (7/9/2019)
  • 2. LADENBURG THALM/SH SH analysts commented, "We are not at all dismayed by the relatively small revenues since there is no stocking for this direct shipment product and hospital formularies barely had an opportunity to meet during these five weeks. Management did note that among the five hospital formularies that did meet, all five have approved Dsuvia. Presently, the company knows of 41 more meetings by midyear. If approved, it will still take weeks to months for AcelRx’s Dsuvia reps to find time with these busy hospital/ASC healthcare practitioners (HCPs), REMS training to be completed (relatively brief however) and the product to be stocked. As many investors know, hospital launches are notoriously slow. However, the early signals are ahead of our expectations." (5/9/2019)

Has AcelRx Pharmaceuticals been receiving favorable news coverage?

Headlines about ACRX stock have trended very negative on Tuesday, InfoTrie reports. The research firm scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AcelRx Pharmaceuticals earned a daily sentiment score of -3.6 on InfoTrie's scale. They also gave news articles about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for AcelRx Pharmaceuticals.

Are investors shorting AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals saw a decline in short interest in the month of September. As of September 30th, there was short interest totalling 13,470,000 shares, a decline of 5.1% from the August 30th total of 14,200,000 shares. Based on an average daily volume of 913,500 shares, the days-to-cover ratio is presently 14.7 days. Currently, 19.1% of the shares of the stock are sold short. View AcelRx Pharmaceuticals' Current Options Chain.

Who are some of AcelRx Pharmaceuticals' key competitors?

What other stocks do shareholders of AcelRx Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AcelRx Pharmaceuticals investors own include Advanced Micro Devices (AMD), Amicus Therapeutics (FOLD), Amarin (AMRN), Novavax (NVAX), TG Therapeutics (TGTX), Cyberark Software (CYBR), Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), Fitbit (FIT) and Flexion Therapeutics (FLXN).

Who are AcelRx Pharmaceuticals' key executives?

AcelRx Pharmaceuticals' management team includes the folowing people:
  • Mr. Vincent J. Angotti, CEO & Director (Age 51)
  • Dr. Pamela Pierce Palmer, Co-Founder, Chief Medical Officer & Director (Age 56)
  • Mr. Raffi Mark Asadorian, Chief Financial Officer (Age 50)
  • Mr. Lawrence G. Hamel, Chief Devel. Officer (Age 67)
  • Mr. Anil N. Dasu, Chief Engineering Officer (Age 56)

How do I buy shares of AcelRx Pharmaceuticals?

Shares of ACRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is AcelRx Pharmaceuticals' stock price today?

One share of ACRX stock can currently be purchased for approximately $2.19.

How big of a company is AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals has a market capitalization of $173.96 million and generates $2.15 million in revenue each year. The specialty pharmaceutical company earns $-47,150,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. AcelRx Pharmaceuticals employs 61 workers across the globe.View Additional Information About AcelRx Pharmaceuticals.

What is AcelRx Pharmaceuticals' official website?

The official website for AcelRx Pharmaceuticals is http://www.acelrx.com/.

How can I contact AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals' mailing address is 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063. The specialty pharmaceutical company can be reached via phone at 650-216-3500 or via email at [email protected]


MarketBeat Community Rating for AcelRx Pharmaceuticals (NASDAQ ACRX)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  413 (Vote Outperform)
Underperform Votes:  337 (Vote Underperform)
Total Votes:  750
MarketBeat's community ratings are surveys of what our community members think about AcelRx Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel